Can a short drug course reverse frailty in childhood cancer survivors?
NCT ID NCT04733534
First seen Jan 22, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study tests two short-term drug combinations (dasatinib plus quercetin, or fisetin alone) in 110 adult survivors of childhood cancer who are frail. The goal is to see if these treatments can reduce signs of cell aging and improve walking speed. The trial is a first step toward a larger, more definitive study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAILTY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.